Liminatus Pharma, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
LIMN Nasdaq 2834 liminatuspharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Liminatus Pharma, Inc.

Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule - Sep 29th, 2026 7:00 am
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy - Aug 24th, 2026 6:00 am
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock - Aug 18th, 2026 2:01 pm
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement - Aug 13th, 2026 5:15 am
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline - Jun 30th, 2026 2:30 pm
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds - Jun 3rd, 2026 6:30 am
Liminatus Pharma Announces Nasdaq Delisting Notification - May 21st, 2026 6:28 pm
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody - Mar 17th, 2026 6:08 am
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering - Feb 17th, 2026 6:44 am
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation - Oct 30th, 2025 8:04 am